Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer — Ioannis Kapelakis (2016) | RDL Network
Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
Article 2016 en
Authors
IK
Ioannis Kapelakis
KT
Konstantinos Toutouzas
MD
Maria Drakopoulou
Abstract
1 min read
The addition of bevacizumab to conventional chemotherapy for metastatic breast or colorectal cancer increases the incidence of cardiovascular events, which is mainly due to the increased prevalence of myocardial infarction and thromboembolic events.
Olivier Núñez, Antonio Román, Simon R. Johnson, Yoshikazu Inoue, Masaki Hirose, Álvaro Casanova, Gorka Ruíz de Garibay, Carmen Herranz, Gema Moreno‐Bueno, Jacopo Boni, Francesca Mateo, Anna Petit, Fina Climent, Teresa Soler, August Vidal, José V. Sánchez‐Mut, Manel Esteller, José I. López, Nadia García, Anna Gumà, Raúl Ortega, M.J. Plà, M. Calvo Campos, Emilio Ansótegui, María Molina‐Molina, Claudia Valenzuela, Piedad Ussetti, Rosalía Laporta, Julio Ancochea, Antoni Xaubet, Marina Pollán, Miguel Ángel Pujana
Discussion(0)
No comments yet. Be the first to comment.